Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2025 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2025.4721
Abstract: Importance Mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) cancers constitute one of the most immunogenic malignancies. Anti-PD-1 monotherapy provides durable responses in a third of patients with advanced dMMR/MSI-H non-colorectal cancers (CRC). Combined anti-PD-1/CTLA-4 blockade using… read more here.
Keywords: anti ctla; dmmr msi; trial; ctla blockade ... See more keywords
Commentary on “CTLA-4 Blockade Suppresses Progression of Residual Tumours after Insufficient RFA”
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular and Interventional Radiology"
DOI: 10.1007/s00270-020-02564-9
Abstract: Image-guided tumour ablation has developed into a wellestablished treatment paradigm for solid cancers. As reflected by the increasing number of key publications in CVIR, several needle-guided thermal and non-thermal ablation techniques have evolved into reliable… read more here.
Keywords: ablation; insufficient rfa; tumour; ctla blockade ... See more keywords
Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of dermatological science"
DOI: 10.1016/j.jdermsci.2017.06.013
Abstract: BACKGROUND The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic… read more here.
Keywords: tumor; response; ctla; transcutaneous immunization ... See more keywords
Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Science"
DOI: 10.1111/cas.15756
Abstract: Combination therapy with anti‐cytotoxic T lymphocyte‐associated protein 4 (CTLA‐4) and anti‐programmed death‐1 (PD‐1) monoclonal antibodies (mAbs) has dramatically improved the prognosis of patients with multiple types of cancer, including renal cell carcinoma (RCC). However, more… read more here.
Keywords: ctla blockade; treg cells; ctla; ctla independent ... See more keywords
Microbiota-dependent activation of CD4+ T cells induces CTLA-4 blockade–associated colitis via Fcγ receptors
Sign Up to like & getrecommendations! Published in 2024 at "Science"
DOI: 10.1126/science.adh8342
Abstract: Immune checkpoint inhibitors can stimulate antitumor immunity but can also induce toxicities termed immune-related adverse events (irAEs). Colitis is a common and severe irAE that can lead to treatment discontinuation. Mechanistic understanding of gut irAEs… read more here.
Keywords: anti ctla; ctla; activation; ctla blockade ... See more keywords
254 CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0254
Abstract: Background Durable clinical responses to immune checkpoint blockade (ICB) occur in a limited fraction of patients. We thus hypothesized that the characteristic tumor metabolic switch towards aerobic glycolysis could contribute to ICB resistance. High glucose… read more here.
Keywords: glycolysis defective; ctla blockade; glycolysis; tumor ... See more keywords
Abstract 5873: LDH inhibition boosts effector T cells while destabilizing regulatory T cells and improves responses to CTLA-4 blockade
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5873
Abstract: Tumor reliance on glycolysis is a hallmark of cancer and a mechanism of resistance to immunotherapy. This resistance is due to lactate-mediated immune suppression and competition for glucose between T cells and tumor cells within… read more here.
Keywords: ctla blockade; cell; tumor; ldh ... See more keywords
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2021010867
Abstract: Relapsed myeloid disease after allogeneic stem cell transplantation (HSCT) remains largely incurable. We previously demonstrated the potent activity of immune checkpoint blockade (ICB) in this clinical setting with ipilimumab or nivolumab. To define the molecular… read more here.
Keywords: molecular cellular; blockade; cellular features; cell ... See more keywords
Distinct TIME Modulation by Anti-PD-1/PD-L1, VEGF, and CTLA-4 Blockade Provides a Rationale for Triplet Therapy in HCC.
Sign Up to like & getrecommendations! Published in 2025 at "Clinical and molecular hepatology"
DOI: 10.3350/cmh.2025.0983
Abstract: PD-L1, VEGF, and CTLA-4 blockade enhances antitumor immunity in HCC by engaging both the priming and effector phases of the cancer-immunity cycle. The findings highlight the importance of understanding how individual regimens modulate the TIME… read more here.
Keywords: triplet therapy; hcc; vegf ctla; ctla blockade ... See more keywords